Balancing moderate HIF-1α activity while promoting HIF-2α for stable angiogenesis and increased EPO could be a promising direction in cardiovascular diseases or overnutrition diseases.6,15,139 This concept is exemplified in heart and kidney management, heart failure treatment, and novel lipid-lowering drugs (Fig. 6b). Here, HIF1A is linked to heart failure.